Speech-Language Pathologists in Van Buren, AR Accepting Medicare
43 Speech-Language Pathologists found. Showing 41 - 43
 Sally Perry Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11 Pointer Trl W, Suite E, Van Buren, AR 72956 Phone: 479-471-1290 Fax: 479-474-5182 |
 Hope Therapy Center Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 816 Fayetteville Rd, Van Buren, AR 72956 Phone: 479-268-2949 Fax: 855-889-4129 |
Kendra L Fanning, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 720 Rena Rd, Van Buren, AR 72956 Phone: 479-471-3190 Fax: 479-471-3193 |
News Archive
Elsevier launches new open access journal dedicated to urology
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of a new open access journal: Urology Case Reports.
New study to assess burden of workplace cancer
To date, there have been no comprehensive studies that have attempted to estimate how many work-related cancers occur in Ontario or Canada-wide. On March 23, 2011 the Occupational Cancer Research Centre (OCRC) is holding a symposium on assessing the human impact of workplace cancer.
Delay in hypothermia, ROSC linked with poor post cardiac arrest neurologic outcomes
Delay in initiation of therapeutic hypothermia and delay in return of spontaneous circulation (ROSC), evidenced by a palpable pulse or a measurable blood pressure, were both associated with poor neurologic outcomes in post cardiac arrest patients, according to a study being presented Nov. 14 at the at the American Heart Association (AHA) scientific sessions in Orlando, Fla.
NSF awards grant to advance new diagnostic test for fatal gastrointestinal disease in pre-term infants
The National Science Foundation has chosen an LSU Health New Orleans team that developed a test for the early detection of a potentially life-threatening gastrointestinal disease affecting pre-term, low birthweight babies to receive expert guidance to move the technology forward.
Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab
The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.
› Verified 8 days ago
Speech-Language Pathologists
Physical Therapists
Occupational Therapists
Optometrists
Chiropractors